In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
Analytics for clinical development strategy: Tools and opportunities
In the final part of the series, CRA’s Dr. Nick Davies presents an overview of current and emerging analytical tools and explores the opportunities for their...